rs370057212
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM5BS2
The NM_002047.4(GARS1):c.1171C>A(p.Arg391Ser) variant causes a missense change. The variant allele was found at a frequency of 0.00000558 in 1,613,978 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R391C) has been classified as Likely pathogenic.
Frequency
Consequence
NM_002047.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GARS1 | ENST00000389266.8 | c.1171C>A | p.Arg391Ser | missense_variant | Exon 9 of 17 | 1 | NM_002047.4 | ENSP00000373918.3 | ||
GARS1 | ENST00000675651.1 | c.1171C>A | p.Arg391Ser | missense_variant | Exon 9 of 17 | ENSP00000502513.1 | ||||
GARS1 | ENST00000675810.1 | c.1069C>A | p.Arg357Ser | missense_variant | Exon 8 of 16 | ENSP00000502743.1 | ||||
GARS1 | ENST00000675693.1 | c.1003C>A | p.Arg335Ser | missense_variant | Exon 10 of 18 | ENSP00000502174.1 | ||||
GARS1 | ENST00000675051.1 | c.970C>A | p.Arg324Ser | missense_variant | Exon 9 of 17 | ENSP00000502296.1 | ||||
GARS1 | ENST00000674815.1 | c.802C>A | p.Arg268Ser | missense_variant | Exon 9 of 17 | ENSP00000502799.1 | ||||
GARS1 | ENST00000674851.1 | c.802C>A | p.Arg268Ser | missense_variant | Exon 10 of 18 | ENSP00000502451.1 | ||||
GARS1 | ENST00000444666.6 | n.1171C>A | non_coding_transcript_exon_variant | Exon 9 of 18 | 3 | ENSP00000415447.2 | ||||
GARS1 | ENST00000674616.1 | n.*885C>A | non_coding_transcript_exon_variant | Exon 10 of 18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.*271C>A | non_coding_transcript_exon_variant | Exon 10 of 17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.*509C>A | non_coding_transcript_exon_variant | Exon 10 of 18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000674807.1 | n.1171C>A | non_coding_transcript_exon_variant | Exon 9 of 16 | ENSP00000502814.1 | |||||
GARS1 | ENST00000675529.1 | n.*1041C>A | non_coding_transcript_exon_variant | Exon 10 of 18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000675859.1 | n.1171C>A | non_coding_transcript_exon_variant | Exon 9 of 15 | ENSP00000502033.1 | |||||
GARS1 | ENST00000676088.1 | n.*1113C>A | non_coding_transcript_exon_variant | Exon 11 of 19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.*116C>A | non_coding_transcript_exon_variant | Exon 9 of 17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.*622C>A | non_coding_transcript_exon_variant | Exon 9 of 17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.*460C>A | non_coding_transcript_exon_variant | Exon 10 of 18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.*603C>A | non_coding_transcript_exon_variant | Exon 9 of 17 | ENSP00000501980.1 | |||||
GARS1 | ENST00000676403.1 | n.1171C>A | non_coding_transcript_exon_variant | Exon 9 of 16 | ENSP00000502681.1 | |||||
GARS1 | ENST00000674616.1 | n.*885C>A | 3_prime_UTR_variant | Exon 10 of 18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.*271C>A | 3_prime_UTR_variant | Exon 10 of 17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.*509C>A | 3_prime_UTR_variant | Exon 10 of 18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000675529.1 | n.*1041C>A | 3_prime_UTR_variant | Exon 10 of 18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000676088.1 | n.*1113C>A | 3_prime_UTR_variant | Exon 11 of 19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.*116C>A | 3_prime_UTR_variant | Exon 9 of 17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.*622C>A | 3_prime_UTR_variant | Exon 9 of 17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.*460C>A | 3_prime_UTR_variant | Exon 10 of 18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.*603C>A | 3_prime_UTR_variant | Exon 9 of 17 | ENSP00000501980.1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152124Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000802 AC: 2AN: 249502Hom.: 0 AF XY: 0.00000739 AC XY: 1AN XY: 135380
GnomAD4 exome AF: 0.00000547 AC: 8AN: 1461854Hom.: 0 Cov.: 31 AF XY: 0.00000550 AC XY: 4AN XY: 727228
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152124Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74316
ClinVar
Submissions by phenotype
not specified Uncertain:1
Variant summary: GARS1 c.1171C>A (p.Arg391Ser) results in a non-conservative amino acid change located in the aminoacyl-tRNA synthetase, class II domain (IPR006195) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function.The variant allele was found at a frequency of 8e-06 in 249502 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.1171C>A in individuals affected with GARS1-Related Disorders and no experimental evidence demonstrating its impact on protein function have been reported. Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Both submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
Charcot-Marie-Tooth disease type 2 Uncertain:1
This sequence change replaces arginine, which is basic and polar, with serine, which is neutral and polar, at codon 391 of the GARS protein (p.Arg391Ser). This variant is present in population databases (rs370057212, gnomAD 0.003%). This missense change has been observed in individual(s) with GARS-related conditions (Invitae). ClinVar contains an entry for this variant (Variation ID: 1053030). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GARS protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not provided Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at